Drug Index


Mechanism :

Imiglucerase is an analogue of the human enzyme, (beta)-glucocerebrosidase produced by recombinant DNA technology. (beta)-Glucocerebrosidase is a lysosomal glycoprotein enzyme which catalyzes the hydrolysis of the glycolipid glucocerebroside to glucose and ceramide.

Indication :

  • Type I Gaucher’s disease

Contraindications :

There are no known contraindications to the use of imiglucerase.

Dosing :

<2 years:
Safety and efficacy not established.
>2 years:
2.5 units/kg given intravenously over 1-2 hours thrice a week or 30-60 units/kg given intravenously every 2 weeks.

Adverse Effect :

Hypersensitivity reactions have been reported, manifested by flushing, pruritus, urticaria, chest discomfort, angioedema, cyanosis, respiratory symptoms, and hypotension. Additional adverse reactions that have been reported include: fatigue, abdominal pain, diarrhea, nausea, backache, rash, headache, dizziness, fever with chills, and tachycardia.

Interaction :

No known drug interactions.

Hepatic Dose :

No dose adjustments are recommended.
02/16/2024 17:17:05 Imiglucerase
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0